The Prostaglandin Receptor EP2 Activates Multiple Signaling Pathways and Beta-arrestin1 Complex Formation During Mouse Skin Papilloma Development

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2009 Jul 10

PMID 19587094

Citations 36

Authors

Kyung-Soo Chun

Huei-Chen Lao

Carol S Trempus

Manabu Okada

Robert Langenbach

Affiliations

Soon will be listed here.

Abstract

Prostaglandin E(2) (PGE(2)) is elevated in many tumor types, but PGE(2)'s contributions to tumor growth are largely unknown. To investigate PGE(2)'s roles, the contributions of one of its receptors, EP2, were studied using the mouse skin initiation/promotion model. Initial studies indicated that protein kinase A (PKA), epidermal growth factor receptor (EGFR) and several effectors-cyclic adenosine 3',5'-monophosphate response element-binding protein (CREB), H-Ras, Src, protein kinase B (AKT) and extracellular signal-regulated kinase (ERK)1/2-were activated in 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted papillomas and that PKA and EGFR inhibition (H89 and AG1478, respectively) decreased papilloma formation. EP2's contributions to the activation of these pathways and papilloma development were determined by inhibiting endogenous TPA-induced PGE(2) production with indomethacin (Indo) and concomitantly treating with the EP2 agonist, CAY10399 (CAY). CAY treatment restored papilloma formation in TPA/Indo-treated mice and increased cyclic adenosine 3',5'-monophosphate and PKA activation as measured by p-CREB formation. CAY treatment also increased EGFR and Src activation and their inhibition by AG1478 and PP2 indicated that Src was upstream of EGFR. CAY also increased H-Ras, ERK1/2 and AKT activation, and AG1478 decreased their activation indicating EGFR being upstream. Supporting EP2's contribution, EP2-/- mice exhibited 65% fewer papillomas and reduced Src, EGFR, H-Ras, AKT and ERK1/2 activation. G protein-coupled receptor (GPCR) activation of EGFR has been reported to involve Src's activation via a GPCR-beta-arrestin-Src complex. Indeed, immunoprecipitation of beta-arrestin1 or p-Src indicated the presence of an EP2-beta-arrestin1-p-Src complex in papillomas. The data indicated that EP2 contributed to tumor formation via activation of PKA and EGFR and that EP2 formed a complex with beta-arrestin1 and Src that contributed to signaling and/or EP2 desensitization.

Citing Articles

Profiling Chemobiological Connection between Natural Product and Target Space Based on Systematic Analysis.

Wang D, Li X, Miao Y, Zhang Q Int J Mol Sci. 2023; 24(14).

PMID: 37511025 PMC: 10378764. DOI: 10.3390/ijms241411265.

Microbial glutamate metabolism predicts intravenous cocaine self-administration in diversity outbred mice.

Tran T, Nguyen H, Sodergren E, Addiction C, Dickson P, Wright S Neuropharmacology. 2023; 226:109409.

PMID: 36592885 PMC: 9943525. DOI: 10.1016/j.neuropharm.2022.109409.

Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling?.

Hou R, Yu Y, Jiang J Biomed Pharmacother. 2022; 156:113966.

PMID: 36411643 PMC: 9682161. DOI: 10.1016/j.biopha.2022.113966.

The Interaction of Human Papillomavirus Infection and Prostaglandin E Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics.

Garcia-Quiroz J, Vazquez-Almazan B, Garcia-Becerra R, Diaz L, Avila E Cells. 2022; 11(16).

PMID: 36010605 PMC: 9406919. DOI: 10.3390/cells11162528.

EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.

Sluter M, Hou R, Li L, Yasmen N, Yu Y, Liu J J Med Chem. 2021; 64(16):11816-11836.

PMID: 34352171 PMC: 8455147. DOI: 10.1021/acs.jmedchem.1c00816.

References

Chang S, Ai Y, Breyer R, Lane T, Hla T . The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 2005; 65(11):4496-9. DOI: 10.1158/0008-5472.CAN-05-0129. View

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello M . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2005; 366(1):2-16. DOI: 10.1016/j.gene.2005.10.018. View

Kennedy C, Zhang Y, Brandon S, Guan Y, COFFEE K, Funk C . Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999; 5(2):217-20. DOI: 10.1038/5583. View

Sung Y, He G, Fischer S . Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res. 2005; 65(20):9304-11. DOI: 10.1158/0008-5472.CAN-05-1015. View

Buchanan F, Gorden D, Matta P, Shi Q, Matrisian L, DuBois R . Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006; 103(5):1492-7. PMC: 1360588. DOI: 10.1073/pnas.0510562103. View

Yuspa S . The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res. 1994; 54(5):1178-89. View

Pelling J, Ernst S, Strawhecker J, Johnson J, Nairn R, Slaga T . Elevated expression of Ha-ras is an early event in two-stage skin carcinogenesis in SENCAR mice. Carcinogenesis. 1986; 7(9):1599-602. DOI: 10.1093/carcin/7.9.1599. View

Luttrell D, Luttrell L . Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene. 2004; 23(48):7969-78. DOI: 10.1038/sj.onc.1208162. View

Matsumoto T, Jiang J, Kiguchi K, Carbajal S, Rho O, Gimenez-Conti I . Overexpression of a constitutively active form of c-src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Mol Carcinog. 2002; 33(3):146-55. DOI: 10.1002/mc.10030. View

10.

Rodriguez-Puebla M, LACAVA M, Bolontrade M, Russell J, Conti C . Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin. Mol Carcinog. 1999; 26(3):150-6. View

11.

Fujino H, Regan J . Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?. Trends Pharmacol Sci. 2003; 24(7):335-40. DOI: 10.1016/S0165-6147(03)00162-7. View

12.

Shoji Y, Takahashi M, Takasuka N, Niho N, Kitamura T, Sato H . Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis. 2005; 26(12):2116-22. DOI: 10.1093/carcin/bgi193. View

13.

El-Abaseri T, Fuhrman J, Trempus C, Shendrik I, Tennant R, Hansen L . Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res. 2005; 65(9):3958-65. DOI: 10.1158/0008-5472.CAN-04-2204. View

14.

Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova I . Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene. 2002; 21(1):53-64. DOI: 10.1038/sj.onc.1205032. View

15.

Mayr B, Montminy M . Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001; 2(8):599-609. DOI: 10.1038/35085068. View

16.

Bourcier C, Jacquel A, Hess J, Peyrottes I, Angel P, Hofman P . p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res. 2006; 66(5):2700-7. DOI: 10.1158/0008-5472.CAN-05-3129. View

17.

Desai S, April H, Nwaneshiudu C, Ashby B . Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol. 2000; 58(6):1279-86. DOI: 10.1124/mol.58.6.1279. View

18.

Kemp C . Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol. 2005; 15(6):460-73. DOI: 10.1016/j.semcancer.2005.06.003. View

19.

Hata A, Breyer R . Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004; 103(2):147-66. DOI: 10.1016/j.pharmthera.2004.06.003. View

20.

Repasky G, Zhou Y, Morita S, Der C . Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Mol Carcinog. 2007; 46(12):958-70. DOI: 10.1002/mc.20333. View